ARTERIA is a French Biopharmaceutical Company dedicated to the development of novel small New Chemical Entities for patients affected by metabolic diseases and Type II Diabetes. The company primary focus is the inhibition of atherosclerotic plaque growth and instability, insulin resistance, glucose intolerance, and lipotoxic cardiomyopathy. ARTERIA is currently completing the preclinical studies of a new series of products, designed to treat patients with atherogenic dyslipidemia. Back-up molecules, achieving similar efficacy for preventing the growth of atherosclerotic plaque are also beeing identified.

ARTERIA has a cutting hedge expertise in cellular High Throughput Screening systems based on reverse-phenotype methodology that can be applied to any chemical library for the identification of novel small molecules.

In addition, ARTERIA has a proprietary technology which allows complex formation between arginine succinic acid and metformin to offer a novel and better therapeutic option to patients with type II diabetes.